Fig 1: Inhibition of autophagy attenuated the inhibitory effect of NVP-BEZ235 on RPL19 expression. (A) G401 cells were treated with NVP-BEZ235 and/or 3-MA, and western blot was used to RPL19 expression detection. (B) G401 cells transfected with sh-ATG5 or sh-NC were treated with NVP-BEZ235, and the expression of RPL19 was detected by western blot. (C) G401 cells were treated with NVP-BEZ235 and/or 3-MA, and immunofluorescence analysis was used to RPL19 expression detection. (D) G401 cells were treated with NVP-BEZ235 and/or MG132, and western blot was used to RPL19 expression detection. (E) The interaction of RPL19 and p62 under the treatment of NVP-BEZ235 was detected by co-immunoprecipitation experiment. Data are presented as mean ± SD of three independent experiments; *P < 0.05.
Fig 2: RPL19 reversed the effect of NVP-BEZ235 on cell cycle. (A) The transfection efficiency of OE-RPL19 in G401 cells was detected by Western blotting. (B) The levels of Cyclin A1, Cyclin B1, and p21 in G401 cells transfected with OE-RPL19 under the treatment of NVP-BEZ235 were detected by western blot. (C) The cell cycle phase in G401 cells transfected with OE-RPL19 after NVP-BEZ235 treatment was determined by flow cytometric analysis. Data are presented as mean ± SD of three independent experiments; *P < 0.05, WT: Wild Type.
Fig 3: NVP-BEZ235 inhibited the growth of nephroblastoma in vivo. (A) Image of the tumor specimen. (B) The tumor volume in each group. (C) The tumor weight in each group. (D) Tumor tissue sections were examined using H&E staining and immunohistochemical staining for Ki67 and RPL19. Data are presented as mean ± SD; *P < 0.05, NC: Negative Control.
Fig 4: RPL19 was overexpressed in nephroblastoma. (A) The RPL19 mRNA expression dataset in nephroblastoma tissues and normal tissues was analyzed by R Studio. (B) RPL19 expression in 5 paired nephroblastoma tissues and corresponding adjacent samples was analyzed by qRT-PCR. (C) RPL19 expression in nephroblastoma tissues and corresponding adjacent samples was analyzed by western blot. The blot shown is representative of three independent biological replicates with technical duplicates. Data are presented as mean ± SD of three independent experiments; *P < 0.05, TA: Tumor Adjacant, T: Tumor.
Supplier Page from Abcam for Anti-RPL19 antibody